Topic summary

Ipamorelin selectivity claims and where they came from

Compounds › Secretagogues & GH axis GHRP class tesamorelin ipamorelin Closed

This is a generated summary. It shows the 8 most-liked posts from a topic of 57, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

t.ibarraTL27 Jan 2025#5

c.wijnberg, post #4: This follows post #3 rather than contradicting it. I would rather this thread reach "we do not know" about ipamorelin selectivity claims than reach a confident answer that nobody can support when asked. Go to post

I read post #3 twice before replying, because I had assumed the opposite.

A request rather than an answer: could whoever has the primary source for ipamorelin selectivity claims post it? I have seen the claim three times this month and each version had lost a qualifier.

28 likes in reply to #4 19mo

f.novakTL226 Feb 2025#16

r.bakken, post #3: Development history is more informative than speculation: ipamorelin was investigated clinically for post-operative ileus and was not taken forward to registration. That it was not brought to market tells you something about the cost-benefit calculation that any amount of forum enthusiasm does not. Go to post

If someone has run ipamorelin selectivity claims properly I would rather read that than my own reconstruction of it. Posting mine only because the thread has gone quiet.

27 likes in reply to #3 17mo

c.inglethorpeTL3Regular21 Mar 2025#22

Effects reported at the level of appetite are the most consistently described and the most mechanistically direct for the ghrelin-receptor compounds, which is not what most people are taking them for.

23 likes 16mo

BGiordanoTL2Member5 Apr 2025#26

KTurkington, post #13: Agreed on ipamorelin selectivity claims, with one qualification that I think matters. The reasoning holds for the case as described. Change the starting assumption and it does not, and the starting assumption is the part nobody states. Go to post

Something worth flagging about ipamorelin selectivity claims: the strongest-sounding claims in this thread are the ones with no source attached, which is the usual pattern and not a coincidence.

31 likes in reply to #13 16mo

lyophil_marginTL3Regular3 May 2025#34

s.bergstrom, post #14: A methods point on ipamorelin selectivity claims rather than a substantive one: if the comparison is not like for like, the difference you are measuring is the difference in method. Go to post

Helpful, and short, which on this subject is harder than long.

33 likes in reply to #14 15mo

j.habermannTL3Regular16 May 2025 · edited#38

a.cardoso, post #20: I had written a reply contradicting post #18 and deleted it. Here is what survived. On analysis: these are short peptides and generally straightforward chromatographically, which means a poor purity result is more likely to reflect the synthesis than the method. Go to post

An honest declaration on ipamorelin selectivity claims: I have a prior here and it is strong enough that you should weight what I say downward. Stating it rather than hiding it.

24 likes in reply to #20 14mo

r.danquahTL230 May 2025 · edited#42

Post #41 answers the question as asked. The question underneath it is different.

Why this subcategory is stricter about sourcing than most: the evidence base is weaker and that is precisely why documentation quality matters more. A supplier page that clearly identifies the compound and the purity is more valuable for secretagogues than for incretin agonists where the evidence base is stronger.

26 likes 14mo

r.chukwuTL212 Jul 2025#56

l.aguirre, post #46: Post #45 is right about the mechanism and I think understates the practical bit. Two things can be true about ipamorelin selectivity claims at once: the mechanism is plausible and the evidence for the size of the effect is thin. Most of the argument here is people defending the first against attacks on the second. Go to post

I had written a reply contradicting post #54 and deleted it. Here is what survived.

My position on ipamorelin selectivity claims is current rather than settled. I have revised it once already and I expect to again, so treat it accordingly.

28 likes in reply to #46 13mo

Read the full topic (57 posts)

This topic was referenced in

Tesamorelin has an approved indication — what that changes about the evidenceCompounds › Secretagogues & GH axis · 27 replies
Coming back to: GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussionCompounds › Secretagogues & GH axis · 13 replies

Promoted into the documentation commons. The content of this topic is maintained at Tesamorelin — reference, with named maintainers and a review date. The promotion was discussed in doc review. Corrections are best raised against the document, which is the version that gets kept current.

This topic was closed 90 days after the last reply. Closing is automatic for quiet topics so that a settled answer does not collect new questions underneath it. If you have a follow-up, open a new topic and link back to this one — that keeps both readable and gives your question its own title.

Suggested topics

Topic	Participants	Replies	Views	Activity
GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion Compounds › Secretagogues & GH axis CJC-1295 observational data ipamorelin needs a source Solved On the subject in the title: GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion Working notes rather than a conclusion. Asking about GHRH analogues versus ghrelin mimetics…	+47	53	6.9k	2h
Why pulsatile secretion matters for interpreting secretagogue claims Compounds › Secretagogues & GH axis CJC-1295 GHRP class tesamorelin Why pulsatile secretion matters for interpreting secretagogue claims — that is the question, and I have not found it answered plainly anywhere I have looked. A follow-up question about pulsatile secretion…	+5	9	1.6k	15h
[2026 update] Evidence quality in the secretagogue literature: an honest assessment Compounds › Secretagogues & GH axis CJC-1295 GHRP class tesamorelin Closed Posting this under the heading it deserves: Evidence quality in the secretagogue literature: an honest assessment Everything below is what sits behind that. I have spent a fortnight trying to pin Evidence…	+14	18	3.1k	6mo
Reading a rodent study on a secretagogue without over-extrapolating Compounds › Secretagogues & GH axis observational data GHRP class CJC-1295 needs a source Closed Posting this under the heading it deserves: Reading a rodent study on a secretagogue without over-extrapolating Everything below is what sits behind that. Reading a rodent study, and specifically the version…	+50	54	32k	10mo
Tesamorelin has an approved indication — what that changes about the evidence Compounds › Secretagogues & GH axis observational data tesamorelin GHRP class CJC-1295 Tesamorelin has an approved indication — what that changes about the evidence — setting out what I have, and where I think it stops being reliable. What changes if the standard account of tesamorelin is…	+23	27	3.4k	1d

Related topics — sharing the tags GHRP class, tesamorelin, ipamorelin

Topic	Participants	Replies	Views	Activity
About the Secretagogues & GH axis category Compounds › Secretagogues & GH axis GHRP class CJC-1295 ipamorelin Pinned Wiki Closed Growth-hormone secretagogues and related compounds. Evidence quality here is markedly lower and we say so. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…	+6	10	1.1k	14mo
Why pulsatile secretion matters for interpreting secretagogue claims Compounds › Secretagogues & GH axis CJC-1295 GHRP class tesamorelin Why pulsatile secretion matters for interpreting secretagogue claims — that is the question, and I have not found it answered plainly anywhere I have looked. A follow-up question about pulsatile secretion…	+5	9	1.6k	15h
IGF-1 as a surrogate endpoint and its limitations — the long version Compounds › Secretagogues & GH axis CJC-1295 observational data ipamorelin needs a source Solved Closed On the subject in the title: IGF-1 as a surrogate endpoint and its limitations — the long version Working notes rather than a conclusion. A narrow question about IGF-1, deliberately narrow, because the broad…	+14	18	53k	12mo
Evidence quality in the secretagogue literature: an honest assessment Compounds › Secretagogues & GH axis ipamorelin observational data GHRP class tesamorelin Solved Evidence quality in the secretagogue literature: an honest assessment Writing it up because I had to work it out twice and would rather nobody else did. I have spent a fortnight trying to pin evidence quality…		2	25k	9d
Why pulsatile secretion matters for interpreting secretagogue claims — a second dataset Compounds › Secretagogues & GH axis GHRP class ipamorelin tesamorelin Under review The question in the title: Why pulsatile secretion matters for interpreting secretagogue claims — a second dataset I will give what I have already checked below so nobody repeats it. Posting a small dataset…	+60	64	25k	15mo